BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.91 USD | -1.53% |
|
-8.71% | -16.09% |
Financials (USD)
| Sales 2024 * | 2.74B | Sales 2025 * | 3.09B | Capitalization | 15.35B |
|---|---|---|---|---|---|
| Net income 2024 * | 358M | Net income 2025 * | 491M | EV / Sales 2024 * | 5.32 x |
| Net cash position 2024 * | 789M | Net cash position 2025 * | 1.36B | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
44.7
x | P/E ratio 2025 * |
31.9
x | Employees | 3,401 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioMarin Pharmaceutical Inc.
More recommendations
More press releases
More news
| 1 day | -1.53% | ||
| 1 week | -8.71% | ||
| Current month | -7.36% | ||
| 1 month | -7.78% | ||
| 3 months | -10.96% | ||
| 6 months | -1.29% | ||
| Current year | -16.09% |
1 week
80.90
93.02
1 month
80.9093.36
Current year
80.9099.25
1 year
76.0299.56
3 years
70.73117.77
5 years
62.88131.95
10 years
55.36151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
| Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | 0.00% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 80.91 | -1.53% | 2,257,132 |
| 24-04-25 | 82.17 | -9.90% | 7,884,498 |
| 24-04-24 | 91.2 | -0.93% | 1,599,632 |
| 24-04-23 | 92.06 | +2.87% | 1,299,078 |
| 24-04-22 | 89.49 | +0.97% | 1,257,361 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
80.91
USD
Average target price
110
USD
Spread / Average Target
+35.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.09% | 15.35B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- BMRN Stock
